Last reviewed · How we verify
INVEGA SUSTENNA
At a glance
| Generic name | INVEGA SUSTENNA |
|---|---|
| Sponsor | Luye Pharma Group Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Injection site reactions
- Somnolence/sedation
- Dizziness
- Akathisia
- Extrapyramidal disorder
- Weight increased
- Nasopharyngitis
- Headache
- Hyperprolactinemia
- Pyrexia
Key clinical trials
- Substance Misuse To Psychosis for Stimulants (PHASE2, PHASE3)
- A Bioequivalence Study of PP3M in Patients With Schizophrenia (NA)
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
- Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia (NA)
- Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia (PHASE4)
- Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |